EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High Concordance of Clinical and Pathological Staging Supports Core Needle Biopsy-Based MammaPrint Testing in Early Breast Cancer

Raquel Weber, Harshini Ramaswamy, Andrea Menicucci, William Audeh

Breast Care · 13.11.2026

DOI: 10.1159/brc/abrag017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Care, online erschienen am 13.11.2026. Verfasst von Raquel Weber und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accurate characterization of early breast cancer (EBC) at diagnosis is essential for timely treatment selection. Genomic profiling assays such as MammaPrint® are increasingly performed on Core Needle Biopsy (CNB) specimens to enable earlier risk stratification and optimized treatment planning. Here we investigated whether clinical staging at diagnosis remains sufficiently consistent with final pathology to support MammaPrint testing on the CNB specimen without awaiting surgical resection.

Methods

Using prospectively collected real-world data from the FLEX Study (NCT03053193), we identified patients with invasive ductal carcinoma and hormone receptor-positive, HER2-negative (HR+/HER2−) disease who had MammaPrint performed on CNB specimens and available clinical and pathologic T and N staging data. Patients who received neoadjuvant therapy or had missing staging information were excluded. We assessed whether tumors remained within the clinically defined MammaPrint-valid population (cT1-cT2 and cN0-cN1) following surgical pathology, with 95% confidence intervals (CIs) calculated using the Wilson score method.

Results

A total of 4,399 FLEX patients were evaluated for tumor staging and 4,238 for nodal staging. Overall, 98.4% of clinical T stage assessments remained within validated T stage ranges at pathologic assessment (pT1-pT2; 4,330/4,399, 95% CI 97.9%-98.8%). The T stage concordance among patients with HR+, HER2- breast cancer was 98.3% (4,003/4,071; 95% CI 97.9%-98.6%). Similarly, 98.0% of clinical N stage assessments remained with validated nodal ranges at pathologic assessment (pN0-pN1; 4,155/4,238, 95% CI 97.5%-98.4%). Among patients with HR+/HER2− breast cancer, clinical N stage concordance within validated testing criteria was 98.0% (3,842/3,921; 95% CI 97.5%–98.3%) at surgical pathology.

Conclusion

In this large real-world cohort, clinical staging at diagnosis reliably identified patients whose disease remained within validated MammaPrint tumor and nodal staging criteria following surgery in 98% of cases. These findings support the reliability of clinical staging to enable genomic testing on CNB specimens at diagnosis, without waiting for definitive surgical pathology.

Zitieren

APA

Weber, R., Ramaswamy, H., Menicucci, A., & Audeh, W. (2026). High Concordance of Clinical and Pathological Staging Supports Core Needle Biopsy-Based MammaPrint Testing in Early Breast Cancer. Breast Care. https://doi.org/10.1159/brc/abrag017

Vancouver

Weber R, Ramaswamy H, Menicucci A, Audeh W. High Concordance of Clinical and Pathological Staging Supports Core Needle Biopsy-Based MammaPrint Testing in Early Breast Cancer. Breast Care. 2026. doi:10.1159/brc/abrag017

BibTeX
@article{Weber2026,
  author = {Weber, Raquel and Ramaswamy, Harshini and Menicucci, Andrea and Audeh, William},
  title = {High Concordance of Clinical and Pathological Staging Supports Core Needle Biopsy-Based MammaPrint Testing in Early Breast Cancer},
  journal = {Breast Care},
  year = {2026},
  doi = {10.1159/brc/abrag017}
}
Kostenlos starten →